Locations:

Clatterbridge Cancer Centre

Who can enter the study?:

Newly diagnosed myeloma patients who are not eligible for high-dose therapy and stem cell transplant (HDT-SCT) and are scheduled to receive standard of care treatment of daratumumab (Darzalex^®), lenalidomide (Revlimid^®) and dexamethasone (DRd).

What's involved?:

All participants will receive standard of care treatment with daratumumab, lenalidomide, and dexamethasone (DRd) for the first 6 treatment cycles (each cycle lasts 28 days).

• Daratumumab is given as a subcutaneous injection (under the skin)
• Lenalidomide is an oral capsule (by mouth)
• Dexamethasone may be given by oral tablets, oral solution (by mouth) or intravenously (into a vein)

iFIT1:

• DRd until myeloma progresses or;
• daratumumab and teclistamab (Tecvayli^®) for a fixed duration followed by monitoring or;
• daratumumab and talquetamab (Talvey^®) for a fixed duration followed by monitoring

iFIT2:

• DRd until myeloma progresses or;
• daratumumab and lenalidomide until myeloma progresses

iFIT3:

• daratumumab and lenalidomide until myeloma progresses or;
• daratumumab and lenalidomide for 18 cycles followed by monitoring

Patients may be followed up for over 10 years.

Clinical Information
(for Medical Professionals):

Personalising treatment for myeloma patients based on initial response to NHS treatment and their overall fitness level (iFIT)

Further information can be found here

Find out more about Myeloma UK:

Visit www.myeloma.org.uk